Результаты поиска

A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.

Pulmonary arterial hypertension (PAH) is a life threatening, progressive condition which eventually leads to fatal right heart failure. Endothelin-1 (ET-1), a potent vasoconstrictor peptide, is increased in the pulmonary arteries of patients with pulmonary hypertension. Endothelin-1 acts through the stimulation of 2 subtypes of receptors (endothelin receptor subtypes A [ET(A)] and B [ET(B)]). In PAH patients, ETRAs block the deleterious vasoconstrictor effects of ET-1, and ETRA treatment in PAH patients has been shown to be safe and efficacious. Sitaxsentan is an orally active, highly ET(A) se

Indications and recent evidence for apheresis in children and adults with kidney diseases: a comprehensive review.

IntroductionPlasmapheresis has been a therapeutic option in kidney diseases to eliminate disease-causing autoantibodies, circulating factors, and abnormal components involved in complement pathways. We aim to systematically review the effectiveness and adverse events associated with plasmapheresis and related apheresis therapies in treating kidney diseases in paediatric and adult populations.MethodsWe searched databases including EMBASE, CINAHL, PubMed, and Cochrane Central for studies from 2010 to October 2023. The search terms included terms related to glomerulonephritis treated with plasmap

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) or bortezomib, lenalidomide and dexamethasone (VRd) is the current standard of care. This phase 3 trial evaluated subcutaneous daratumumab plus VRd (D-VRd) in patients with transplant-ineligible NDMM or for whom transplant was not planned as the initial therapy (transplant deferred). Some 395 patients wi

Current and emerging treatment options for patients with relapsed myeloma.

Multiple myeloma (MM) is a neoplastic disorder. It results from proliferation of clonal plasma cells in bone marrow with production of monoclonal proteins, which are detectable in serum or urine. MM is clinically characterized by destructive bone lesions, anemia, hypercalcemia and renal insufficiency. Its prognosis is severe, with a median survival after diagnosis of approximately 3 years due to frequent relapses. Treatments for patients with relapsed/refractory MM include hematopoietic cell transplantation, a rechallenge using a previous chemotherapy regimen or a trial of a new regimen. The i

Нацеливание БКМА на многочисленные миеломы: всеобъемлющий обзор иммунотерапевтических стратегий и клинических результатов.

Множественная миелома (ММ) является второй по распространенности гематологическая гелингология и остается неизлечимой, что подчеркивает настоятельную потребность в новых терапевтических стратегиях. В. Антиген созревания клеток (BCMA), выраженный преимущественно на зрелых лимфоцитах B, играет важнейшую роль в активации и созревании клеток B. Растущие данные указывают на участие BCMA в росте опухоли, метастазе и раковом стебле, что делает его многообещающей терапевтической целью. В настоящем обзоре содержится всеобъемлющий обзор ориентированных на БКМА иммунотерапевтических стратегий в ММ, включ

New Insights Into the Role of Neutrophils in Lymphoma.

Under physiological conditions, neutrophils exhibit remarkable tissue surveillance capabilities, infiltrating interstitial spaces within secondary lymphoid organs such as lymph nodes and spleen, and even actively patrolling nodal tissues. These observations provide groundbreaking insight into the functional heterogeneity of neutrophils while offering new perspectives on the tumor microenvironment (TME) in lymphomas. A critical question arises: what roles might these specialized, lymphoid tissue-resident neutrophils play in lymphomagenesis through their unique phenotypic and functional adaptati

Cardiotoxicity of Novel Targeted Hematological Therapies.

Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to chronic conditions, such as heart failure or hypertension, which dramatically reduce quality of life of cancer survivors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability, while new targeted therapies work by interfering with signaling pathways

ISEV2020 Резюме

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.

Natural Killer (NK) cells are exciting candidates for cancer immunotherapy with potent innate cytotoxicity and distinct advantages over T cells for Chimeric Antigen Receptor (CAR) therapy. Concerns regarding the safety, cost, and scalability of viral vectors has ignited research into non-viral alternatives for gene delivery. This review comprehensively analyses recent advancements and challenges with non-viral genetic modification of NK cells for allogeneic CAR-NK therapies. Non-viral alternatives including electroporation and multifunctional nanoparticles are interrogated with respect to CAR

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT). Clinical trials conducted in the first ten years of the twenty-first century established as standard therapy for these patients a therapeutic approach including induction, single or double ASCT, consolidation, and maintenance therapy. More recently, incorporating second-generation proteasome inhibitors carfi

Case Report: Cord blood-derived natural killer cells as new potential immunotherapy drug for solid tumor: a case study for endometrial cancer.

Adoptive transfer of natural killer (NK) cells represents a viable treatment method for patients with advanced malignancies. Our team previously developed a simple, safe, and cost-effective method for obtaining high yields of pure and functional NK cells from cord blood (CB) without the need for cell sorting, feeder cells, or multiple cytokines. We present the case of a 52-year-old female patient diagnosed with poorly differentiated stage IVB (T3N2M1) endometrial cancer, who exhibited leukemoid reaction and pretreatment thrombocytosis as paraneoplastic syndromes. The patient received two cours

From Selection to Use: Aptamers as Targeting Reagents in Hematology.

Aptamers are synthetic nucleic acid ligands that have been proposed as alternatives to antibodies for targeting molecules and cells. In hematology, most reviews have organized aptamer literature around diseases or technological platforms. This framing has obscured how unevenly different blood cell types have been covered. In this review, we present developed aptamers organized by blood cell lineages. Specifically, we examine aptamers for B cells, T cells, natural killer cells, and red blood cells. This organization revealed a strong concentration on a small set of canonical surface markers and

Critically Ill Immunosuppressed Host

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Endodontics in Systemically Compromised Patients

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Antibodies to watch in 2023.

In this 14th installment of the annual Antibodies to Watch article series, we discuss key events in commercial monoclonal antibody therapeutics development that occurred in 2022 and forecast events that might occur in 2023. As of mid-November, 12 antibody therapeutics had been granted first approvals in either the United States or European Union (tebentafusp (Kimmtrak), faricimab (Vabysmo), sutimlimab (Enjaymo), relatlimab (Opdualag), tixagevimab/cilgavimab (Evusheld), mosunetuzumab (Lunsumio), teclistamab (TECVAYLI), spesolimab (SPEVIGO), tremelimumab (Imjudo; combo with durvalumab), nirsevim

Review of cancer therapies for the perioperative physician.

Advances in cancer treatments over the past decades combining chemotherapy with novel technologies in immunotherapies, radiation therapies, and interventional radiology have prolonged life expectancy. Patients have more options for treatments of their primary or metastatic diseases. Increased procedural techniques amid an aging population with multiple comorbidities present risks and challenges in the perioperative period.Chemotherapy remains the mainstay of cancer treatment, can be given intraoperatively, and is combined with other treatment modalities. Immunotherapy is particular to cancer c

Первичная линия Daratumumab, линалидомид и дексаметасон у пациентов старше 80 Годы с недавно диагностированной множественной миеломой: износостойкость лечения, инфекционные осложнения и пищевая уязвимость.

ЦЕЛЬ: Оценка эффективности, долговечности лечения и инфекционных осложнений прифронтовой линии Daratumumumab, lenalidomide и dexametasone (DRd) у пациентов пожилого возраста > 80 годы с недавно поставленным диагнозом множественной миэломы (Ti-NDMM) и исследованием связей между базовой пищевой уязвимостью и результатами лечения. Мы ретроспективно проанализировали пациентов в возрасте > 80 годами с Ti-NDMM, получившим передний DRd. Были также оценены результаты лечения и инфекционные осложнения. Исследовательный анализ проводился в соответствии с базовыми индексами питания, включая индекс прогно

Совпадение в полном тексте источника
… Filgrastim was administered to seven patients, and no platelet transfusions were required. None of the patients received antiviral prophylaxis or IgRT during DRd treatment. …

Multimodal imaging diagnosis of multiple myeloma with renal involvement: a case report.

BackgroundExtramedullary renal involvement secondary to multiple myeloma (MM) is extremely rare and prone to preoperative misdiagnosis. Its clinical and imaging manifestations have not been systematically summarized, leading to frequent preoperative misdiagnosis. To summarize the multimodal imaging characteristics and clinical diagnostic value of MM with renal involvement through a typical case report, so as to improve the understanding and early recognition rate of this disease.Case presentationA 67-year-old male patient with left lumbodorsal pain was examined by multimodal imaging. Ultrasoun

Prehabilitation to improve outcomes afteR Autologous sTem cEll transplantation (PIRATE): A pilot randomised controlled trial protocol.

BackgroundAutologous stem cell transplant is a common procedure for people with haematological malignancies. While effective at improving survival, autologous stem cell transplant recipients may have a lengthy hospital admission and experience debilitating side-effects such as fatigue, pain and deconditioning that may prolong recovery. Prehabilitation comprising exercise and nutrition intervention before stem cell transplant aims to optimise physical capacity before the procedure to enhance functional recovery after transplant. However, few studies have evaluated prehabilitation in this settin

Elements for assistance to patients with hematological malignancies to propose care lines: a scoping review.

Objectivesto identify the elements for assistance to patients with hematological malignancies to propose a care line.Methodsthis is a scoping review, anchored in the JBI theoretical framework, with searches carried out in April 2021, in eight electronic databases and 10 repositories of theses and dissertations.Resultsthe final sample consisted of 93 studies, and the main forms of assistance provided that can support a care line for this public were imaging tests, immunophenotyping, chemotherapy regimens, radiotherapy, infection management, assessment of nutritional status, maintenance of oral

Совпадение в полном тексте источника
… A72 † / 2016 / England | Support Use low-dose prophylactic platelet transfusions for thrombocytopenic patients due to myelosuppressive chemotherapy or stem cell transplantation. …